ReviewOncogene2018
Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics.
Review in Oncogene, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 237 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
237 citing papers in PubMed, 2 syntheses or guidelines pooled it, 383 citations in OpenAlex.
- The role of FAPI PET/CT in patients with lymphoma: a systematic review.Frontiers in nuclear medicine · 2025Pooled it
- State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2021Pooled it
- Feasibility and therapeutic potential of [European journal of nuclear medicine and molecular imaging · 2024Trial
- Diagnostic efficacy of [European journal of nuclear medicine and molecular imaging · 2024Trial
- A head-to-head comparison of [European journal of nuclear medicine and molecular imaging · 2024Trial
- Optimizing FAPI homodimers for theranostic applications: The impact of the linker design in DOTAGA.GluEuropean journal of nuclear medicine and molecular imaging · 2026Article
- The value of fibroblast activation protein inhibitor-based radionuclide theranostics in sarcoma: a systematic review.Annals of nuclear medicine · 2026Review
- FAPExperimental & molecular medicine · 2026Article
- FAP-Inhibitor Homodimers with Engineered Linker-Spacer Units: Toward Optimized Radiopharmaceuticals.ACS omega · 2026Article
- The Evolution of FAP-Targeted CAR T-Cell Therapy in Solid Tumors: From Immunotherapy to Immunotheranostic Applications.International journal of molecular sciences · 2026Review
- Tuning the Structural Properties of a Single-Domain Antibody Scaffold for Improved Fibroblast Activation Protein Targeting.Molecular pharmaceutics · 2026Article
- Article
- Fibroblast activation protein expression in fibrotic foci is a prognostic marker of fibrotic changes in lung tissue after surgical treatment for cancer.Surgery today · 2026Article
- Inhibition of fibroblast activation protein partially restores the homeostatic phenotype of mechanoactivated synoviocytes.Osteoarthritis and cartilage · 2026Article
- Targeting FAPActa pharmaceutica Sinica. B · 2026Article
- Dual-time-point 68Ga-FAPI PET/CT in gastrointestinal malignancies: head-to-head comparison with 18 F-FDG for lesion detection and patient-level assessment.Annals of nuclear medicine · 2026Article
- Automated and manual synthesis of [EJNMMI radiopharmacy and chemistry · 2026Article
- Article
- The Use of FAPi PET-CT in Recurrent Malignant Uterine PEComa.Clinical nuclear medicine · 2026Article
- Article
177 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Fibroblast activation protein (FAP) is a cell-surface serine protease that acts on various hormones and extracellular matrix components. FAP is highly upregulated in a wide variety of cancers, and is often used as a marker for pro-tumorigenic stroma. It has also been proposed as a molecular target of cancer therapies, and, especially in recent years, a great deal of research has gone into design and testing of diverse FAP-targeted treatments. Yet despite this growing field of research, our knowledge of FAP's basic biology and functional roles in various cancers has lagged behind its use as a tumor-stromal marker. In this review, we summarize and analyze recent advances in understanding the functions of FAP in cancer, most notably its prognostic value in various tumor types, cellular effects on various cell types, and potential as a therapeutic target. We highlight outstanding questions in the field, the answers to which could shape preclinical and clinical studies of FAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.